Skip to main content
. 2018 Dec 21;24(47):5403–5414. doi: 10.3748/wjg.v24.i47.5403

Table 3.

Fecal microbiota implantation success and failure

Valid No. Success
 Failure
 P value
Number % Number %
Patients 111 111 97 87.42 14 12.6
Male gender 111 47 40 41.23 7 50.0 0.535
Ambulatory 111 78 72 92.32 6 7.7 0.016
Hospitalized 111 33 25 75.82 8 24.2
CDI risk factors
Prior hospitalization 111 80 68 70.13 12 85.7 0.224
Antibiotics use 108 89 77 81.13 12 92.3 0.318
PPI usage 110 37 32 33.33 5 35.7 0.86
Chemotherapy 111 19 17 17.53 2 14.3 0.764
IBD 111 20 18 18.63 2 14.3 0.698
Steroid usage 111 17 13 13.43 4 28.6 0.141
Fever 76 21 19 27.93 2 25.0 0.86
Severe disease 111 20 14 14.43 6 42.9 0.01
Death 111 11 6 6.23 5 37.5 0.001
Adverse events 107 19 15 16.03 4 30.8 0.19
Route: Lower GI FMT 111 50 45 88.02 5 12.0 0.338
Upper GI FMT1 111 24 19 79.22 5 20.8
Capsules FMT 111 37 34 91.92 3 8.1
Frozen stool 111 91 81 89.02 10 11.0 0.272
Fresh stool 111 20 16 80.02 4 20.0
0-1 Previous CDI 107 24 23 24.23 1 8.3 0.214
2+ previous CDI 107 83 72 74.23 11 78.6
Indication 0.824
Refractory 111 29 25 86.22 4 13.8
Recurrent 111 82 72 87.82 10 12.2
Prior therapy
Metronidazole 110 89 80 83.33 9 64.3 0.09
Vancomycin 110 109 95 99.03 14 100.0 0.701
Combination 109 31 27 28.13 4 30.8 0.843
Valid Mean SD Mean SD Sigma
Age (yr) 111 63.2 22.4 73.7 12.1 0.089
Charlson comorbidity score 81 4.82 3.18 6.6 2.32 0.048
Previous CDI episodes (n) 107 2.47 1.7 2.38 0.9 0.864
Time from 1st CDI (d) 89 140.4 200.8 108.56 120.3 0.643
Creatinine (mgl/dL) 76 1.37 1.2 2.19 2.6 0.098
Albumin (mg/L) 54 3.32 0.8 2.76 0.5 0.053
WBC (103/dL) 76 13.6 18.7 15.6 10.4 0.756
1

Upper GI: Gastroscopy, nasogastric tube or through percutaneous endoscopic gastrostomy;

2

Percentages referral is the total number of subjects in the cohort;

3

Percentages referral is the number of subjects in the specific group. CDI: Clostridium difficile infection; IBD: Inflammatory bowel diseases; PPI: Proton pump inhibitor; GI: Gastrointestinal; FMT: Fecal microbiota implantation; IQR: Interquartile range; WBC: White blood cells; Prior hospitalization: Hospitalization during the 3 mo prior to the FMT; Prior hospitalization: Antibiotics use in the 3 mo prior to the FMT.